Merck Q4 2023 Earnings February 1, 2024 -- 1 of 32 -- Agenda 2 Strategy and Business Update Rob Davis Chairman and Chief Executive Officer Question & Answer Session Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer Research Update Dr. Dean Li President, Merck Research Laboratories -- 2 of 32 -- Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA 3 This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov). -- 3 of 32 -- Strategy and Business Update Rob Davis Chairman and Chief Executive Officer -- 4 of 32 -- Committed to saving and improving lives around the world 5 More than 500 million people reached with our medicines in 2023 -- 5 of 32 -- Delivered on our key strategic priorities in 2023 Advanced the pipeline to meet patient unmet need Achieved strong commercial and financial performance Executed on strategic business development to augment pipeline Created long-term value for patients and shareholders 6 -- 6 of 32 -- 0 10,000 20,000 30,000 40,000 50,000 60,000 70,000 2021 2022 2023 2024 Strong 2023 underlying performance1 and 2024 initial guidance 7 1. Results from continuing operations attributable to Merck & Co., Inc. 2. Excludes LAGEVRIO sales of $193 million in 4Q23 and $825 million in 4Q22. 3. Merck does not exclude expenses for upfront and milestone payments related to certain collaborations and licensing agreements, or charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Full year non-GAAP results for 2023, 2022 and 2021 include $6.21, $0.22 and $0.65 per share of such charges, respectively. 4. GAAP Loss per Share ($0.48). $14.6B +6% +13% ex-Exchange, ex-LAGEVRIO 2 Q4 Worldwide Sales $0.03 Includes one-time charge of $1.69 per share from the collaboration with Daiichi Sankyo Q4 Non-GAAP EPS4 $48.7B +17% $5.37 Full Year Sales Full Year Non-GAAP EPS3 $59.3B +22% $60.1B +1% 2021 2022 2023 2024 $1.51 $5.37 $7.48 GUIDANCE RANGE $62.7B - $64.2B +4% - +7% GUIDANCE RANGE $8.44 - $8.59 -- 7 of 32 -- 8 Maximizing potential impact for patients with our expansive pipeline Vaccines Cardiometabolic Oncology Sotatercept Seeking to transform treatment paradigm for patients with pulmonary arterial hypertension V116 Pursuing approval for the first pneumococcal conjugate vaccine specifically designed for adults Diverse Portfolio & Pipeline Broadening reach to more patients with potential to improve outcomes -- 8 of 32 -- Expanding robust pipeline with opportunity for patient impact and value creation well into the next decade 9 Oncology (excludes innovation from marketed products) Cardiometabolic Immunology Prior Outlook Current Outlook >$10B Includes TROP-21 , ROR-1, CYP11A1i2, LSD-1i, KRASi, BTKi and others >$20B Now includes HER3, B7H3 and CDH6 ADCs3 and V940 (INT) 4 ~$15B Now includes MK-6024, and reflects increased confidence supported by clinical data readouts for sotatercept and MK-0616 >$10B Includes sotatercept, MK-0616, MK-2060, MK-5475 and Verquvo5 Multibillion in each indication (CD and UC) for tulisokibart Multibillion in each indication (CD and UC) for tulisokibart Additional Opportunities in Late-Phase Pipeline Programs Across Vaccines, Neurosciences, HIV and Animal Health, Early-Phase Programs & Additional Potential Business Development Note: All dollar figures above are non-risk adjusted annual sales by the mid 2030s 1. Collaboration with Kelun Biotech 2. Collaboration with Orion 3. Collaboration with Daiichi Sankyo 4. Collaboration with Moderna 5. Collaboration with Bayer, includes expanded indication to chronic heart failure without a worsening event for Verquvo -- 9 of 32 -- Business/Financial Results and Outlook Caroline Litchfield Chief Financial Officer -- 10 of 32 -- Strong underlying Q4 and 2023 worldwide sales growth 11 4Q 2023 WORLDWIDE SALES1 $14.6B+6% growth +11% ex-LAGEVRIO3 +13% ex-exchange, ex-LAGEVRIO 3 $13.1B +8% growth +14% ex-LAGEVRIO 3 +14% ex-exchange, ex-LAGEVRIO 3 Human Health $1.3B +4% growth +4% ex-exchange Animal Health 1. Worldwide Sales includes Other Revenue. 2. Excludes LAGEVRIO sales of $1.4 billion in 2023 and $5.7 billion in 2022. 3. Excludes LAGEVRIO sales of $193 million in 4Q23 and $825 million in 4Q22. FULL YEAR WORLDWIDE SALES1 $60.1B+1% growth +9% ex-LAGEVRIO2 +12% ex-exchange, LAGEVRIO2 Merck -- 11 of 32 -- Oncology: KEYTRUDA continues to benefit patients globally 12 Growth rates exclude the impact of foreign exchange. • KEYTRUDA sales of $6.6B increased 22% driven by global uptake in earlier stage cancers, including TNBC and RCC, and strong global demand from metastatic indications • Encouraging signs in treating certain patients with earlier stage NSCLC based on recent approvals • Positive initial feedback from healthcare providers following recent launch in advanced urothelial cancer $4.2B +20% $3.4B +31% $5.3B +30% 4Q21 4Q22 4Q23 $5.5B +26% $4.6B +16% $6.6B +22% -- 12 of 32 -- Oncology: Solid performance across broad portfolio • Lynparza 1 sales grew 8% driven primarily by pricing in the U.S. and higher demand in international markets • Lenvima 2 sales grew 5% driven by higher demand in the U.S., partially offset by shipment timing in China • WELIREG sales increased 78% driven by increased uptake in VHL-associated tumors – Opportunity to treat certain patients with previously treated advanced RCC based on LITESPARK-005 $181M +15% $151M +57% 13 Growth rates exclude the impact of foreign exchange. 1. In collaboration with AstraZeneca 2. In collaboration with Eisai 4Q21 4Q22 4Q23 $292M +14% $268M +33% $315M +8% 4Q21 4Q22 4Q23 $216M +9% $206M +31% $226M +5% 4Q21 4Q22 4Q23 $40M +245% $12M $72M +78% -- 13 of 32 -- Vaccines: Robust growth driven by GARDASIL 14 • GARDASIL sales of $1.9B increased 27% year-over-year driven by strong global demand, particularly in China – In the U.S., sales benefited from CDC purchasing patterns • VAXNEUVANCE growth driven by launches in Europe and continued uptake of pediatric indication in the U.S. – 4Q 2022 benefited from inventory stocking in the U.S. ahead of pediatric launch $1.2B +78% $656M -24% $1.7B +40% 4Q21 4Q22 4Q23 $1.5B +6% $1.5B +50% $1.9B +27% Growth rates exclude the impact of foreign exchange. -- 14 of 32 -- Hospital: Continued patient impact across portfolio 15 • BRIDION sales declined 3% as increased market share among neuromuscular blockade reversal agents in the U.S. was more than offset by the impact of generic entrants in international markets, particularly in Europe • PREVYMIS sales grew 49% driven by continued strong global demand $387M +67% $224M -18% $426M +15% 4Q21 4Q22 4Q23 $441M +7% $436M +24% $429M -3% $93M +41%$63M +67% $103M +18% $94M +20% $82M +31% $129M +44% Increase/decrease excludes the impact of foreign exchange. 4Q21 4Q22 4Q23 $118M +28%$100M +27% $175M +49% -- 15 of 32 -- Animal Health: Solid growth driven by companion animal 16 • Animal Health sales increased 4% to $1.3B – Companion Animal sales increased 12% driven by BRAVECTO line of products due to strong underlying demand and shipment timing – Livestock sales were flat reflecting favorable price actions offset by timing of ruminant product shipments $1.5B +27% $1.1B +3% $1.5B +5% 4Q21 4Q22 4Q23 $1.2B +6% $1.3B +8% $1.3B +4% Growth rates exclude the impact of foreign exchange. -- 16 of 32 -- Q4 2023 non-GAAP financial results summary1 Q4 2023 Q4 2022 Change Change Ex-FX Sales $14.6 $13.8 +6% +7% Non-GAAP Gross Margin 77.2% 75.7% +1.5pts +2.5pts Non-GAAP Operating Expenses $11.6 $5.7 >100% >100% Non-GAAP Tax Rate 114.2% 15.6% >100% N/A Non-GAAP EPS2,3 $0.03 $1.62 -98% >100% $ in billions, except EPS amounts 17 1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to the earnings release. 2. Q4 2023 includes $5.5 billion charge, or $1.69 negative EPS impact, for the collaboration with Daiichi Sankyo. 3. Q4 2023 GAAP Loss per Share of ($0.48). -- 17 of 32 -- Initial 2024 financial outlook implies strong growth 1. Guidance does not assume any additional significant potential business development transactions. 2. One royalty on KEYTRUDA stepped down from 6.5% to 2.5% on 1/1/2024; One royalty on GARDASIL expired on 1/1/2024. 18 Guidance Key Assumptions Revenue $62.7B to $64.2B • Implies growth of +4% to +7% (+6% to +9% ex-FX) • Assumes ~2 ppt FX headwind Non-GAAP Gross Margin Rate ~80.5% • Includes the benefit from reduced royalties paid on KEYTRUDA and GARDASIL2 Non-GAAP Operating Expenses1 $25.1B to $26.1B • Includes ~$650M one-time charge related to the announced acquisition of Harpoon Therapeutics Other (Income) / Expense ~$200M of expense Tax Rate ~14.5% to 15.5% Shares Outstanding ~2.54B Non-GAAP EPS $8.44 to $8.59 • Includes one-time ~$0.26 charge related to Harpoon Therapeutics • Includes a negative impact from FX of ~$0.25 -- 18 of 32 -- 19 Augmenting our pipeline with value enhancing business development while continuing to invest in our pipeline and business $2.8 $1.0 $1.9 $5.6 $0.4 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Q4 Spend ($ in billions): 1. Reflects R&D excluding Business Development Remain committed to balanced capital allocation strategy Capital allocation order of priority 1 -- 19 of 32 -- Research Update Dr. Dean Li President, Merck Research Laboratories -- 20 of 32 -- Diversifying our oncology program and executing on our strategy Precision Molecular Targeting Impact pathways that can drive cancer growth Tissue Targeting Increase cancer cell sensitivity with ADCs and immune-engagers Immuno-oncology Boost anti-tumor immune responses quavonlimab/pembro (MK-1308A) anti-CTLA-4 vibostolimab/pembro (MK-7684A) anti-TIGIT MK-4830 anti-ILT-4 zilovertamab vedotin (MK-2140) ROR1 ADC nemtabrutinib (MK-1026) BTK inhibitor MK-56844 CYP11A1 inhibitor V9401 Individualized Neoantigen Therapy MK-1484 IL-2 Rβɣ bomedemstat (MK-3543) LSD1 inhibitor MK-5890 CD27 agonist 21 1. Collaboration with Moderna 2. Collaboration with AstraZeneca 3. Collaboration with Eisai 4. Collaboration with Orion 5. Collaboration with Kelun Biotech 6. Includes internal pipeline programs 7. Collaboration with Daiichi Sankyo 8. Pending close of the acquisition of Harpoon Therapeutics 9. Collaborations with Dragonfly and Janux and others 2 3 MK-1084 KRAS G12C inhibitor MK-28705 TROP2 ADC MK-24007 B7H3 ADC MK-12005 Claudin 18.2 ADC Undisclosed preclinical ADC targets5,6 MK-59097 CDH6 ADC favezelimab/pembro (MK-4280A) anti-LAG-3 Bi-and tri- specific T & NK cell engagers9 MK-10227 HER3 ADC MK-31205 Nectin-4 ADC HPN3288 DLL3 -- 21 of 32 -- Ongoing commitment to harnessing the power of immuno-oncology 22 Recent Approvals Earlier Stage Data • KEYNOTE-859: FDA and EC approved KEYTRUDA in combination with chemotherapy for first-line treatment of adults with locally advanced unresectable or metastatic HER2 negative gastric or GEJ adenocarcinoma • KEYNOTE-966: FDA and EC approved KEYTRUDA in combination with gemcitabine and cisplatin for treatment of patients with locally advanced unresectable or metastatic biliary tract cancer • KEYNOTE-A18: FDA approved KEYTRUDA in combination with chemoradiotherapy for treatment of patients with FIGO 2014 Stage III through IVA cervical cancer • KEYNOTE-671: Demonstrated statistically significant improvement in OS as perioperative treatment regimen for patients with resectable stage II, IIIA or IIIB (N2) NSCLC vs preoperative chemotherapy • KEYNOTE-564: Demonstrated statistically significant improvement in OS as post-surgery adjuvant treatment regimen for certain patients with RCC vs placebo • KEYNOTE-123: Demonstrated statistically significant improvement in DFS vs observation as adjuvant treatment for high-risk patients with localized muscle invasive and locally- advanced resectable urothelial carcinoma • KEYNOTE-942: Announced positive three year follow-up data for V940 1 in combination with KEYTRUDA for patients with resected high-risk stage III or IV melanoma following complete resection 1. Collaboration with Moderna -- 22 of 32 -- 23 Important progress in precision and tissue targeting 1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. Collaboration with Daiichi Sankyo Precision Molecular Targeting Tissue Targeting • LITESPARK-005: Received FDA approval for WELIREG for treatment of adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-TKI - Additional Phase 3 trials planned for WELIREG in combination with KEYTRUDA and/or lenvatinib in advanced and adjuvant settings • KEYNOTE-A391: Received FDA approval for KEYTRUDA in combination with enfortumab vedotin in 1L locally advanced or metastatic urothelial cancer • HERTHENA-Lung01: Received priority review for MK-1022 (patritumab deruxtecan2) for treatment of patients with advanced EGFR-mutated NSCLC previously treated with two or more systemic therapies • Announced pending acquisition of Harpoon Therapeutics, which includes lead candidate HPN328, a T-cell engager targeting (DLL3) being evaluated in SCLC and neuroendocrine tumors -- 23 of 32 -- V116 Sotatercept • Granted priority review for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults (PDUFA June 17th) • Additional data from STRIDE-3 as well as STRIDE-4, STRIDE- 5 and STRIDE-6 to be presented at ISPPD1 in March • Potential to be first approved pneumococcal conjugate vaccine specifically designed for adults, protecting against ~83% of adult invasive pneumococcal disease for those 65+2 • Under priority review for treatment of PAH (PDUFA March 26th) • Ongoing Phase 3 ZENITH and HYPERION studies, as well as Phase 2 CADENCE study 24 Notable progress across our vaccines and cardiometabolic programs 1. International Society of Pneumonia & Pneumococcal Diseases 2. According to CDC data from 2018-2021 -- 24 of 32 -- Significant progress across our broad pipeline in 2023 25 >25 >20 Regulatory approvals in major markets Phase 3 studies initiated across multiple new asset classes Planning to initiate an even greater number of Phase 3 trials in 2024 -- 25 of 32 -- Q&A Rob Davis Chairman & Chief Executive Officer Caroline Litchfield Chief Financial Officer Dr. Dean Li President, Merck Research Laboratories Peter Dannenbaum Vice President, Investor Relations -- 26 of 32 -- Appendix 27 -- 27 of 32 -- Q4 2023 GAAP financial results summary 28 Q4 2023 Q4 2022 Change Change Ex-FX Sales $14.6 $13.8 +6% +7% Operating Expenses $12.4 $6.5 +92% +92% Tax Rate 40.1% 14.1% >100% N/A GAAP (Loss) / Earnings per Share ($0.48) $1.18 >100% >100% $ in billions, LPS/EPS amounts -- 28 of 32 -- 2023 GAAP financial results summary 29 2023 2022 Change Change Ex-FX Sales $60.1 $59.3 +1% +4% Operating Expenses $41.0 $23.6 +74% +75% Tax Rate 80.0% 11.7% >100% N/A GAAP Earnings per Share $0.14 $5.71 -98% -95% $ in billions, EPS amounts -- 29 of 32 -- $10.4 $3.9 $7.4 $18.5 $1.3 $0 $3 $6 $9 $12 $15 $18 $21 After-Tax R&D CapEx Dividends Paid Business Development (ex-divestitures) Share Repurchase Capital allocation: Trailing twelve months ~$ 18B Over 5 years, including expanding manufacturing capacity for Oncology, Vaccines, and Animal Health. Includes >$10B in the U.S. Billions $1.76 $1.80 $1.84 $1.88 $1.92 $2.20 $2.44 $2.60 $2.76 $2.92 $1.40 $1.70 $2.00 $2.30 $2.60 $2.90 $3.20 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Dollars per share +2% +2% +2% +2% +2% +11% +15% +7% Over the past 12 months Capital investments 2023 to 2027 Commitment to the dividend 30 Well positioned balance sheet with capacity to fund additional value-enhancing business development opportunities +6% Order of priority +6% 1. Includes payments reflected in operating cash flow 2. Reflects R&D excluding Business Development 1 2 E -- 30 of 32 -- Driving value for patients and shareholders by progressing our pipeline 31 Key regulatory milestones since the last earnings call: Key data & clinical advancements since the last earnings call: • In the U.S.: o Approved KEYTRUDA in combination with gemcitabine and cisplatin for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer based on KN-966. o Approved KEYTRUDA in combination with chemotherapy for the 1L treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma based on KN-859. o Approved KEYTRUDA in combination with Padcev for the treatment of adult patients with locally advanced or metastatic urothelial cancer based on KN-A39/EV-3021 . This approval moves the indication to full approval from previous accelerated approval based on KN869/EV- 1031 for cisplatin-ineligible patients. o Approved KEYTRUDA for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than PD-1/PD-L1 containing regimen based on KN- 394. This approval moves the indication to full approval from previous accelerated approval based on KN-224 and did not include patients with HCC secondary to hepatitis B. o Approved KEYTRUDA in combination with chemoradiotherapy for the treatment of patients with FIGO 2014 stage III-IVA cervical cancer based on KN-A18. o Approved WELIREG for the treatment of adult patients with advanced renal cell carcinoma following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI based on LITESPARK-005. o Accepted for priority review the BLA for MK-1022 (patritumab deruxtecan 2 ) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer previously treated with two or more systemic therapies based on HERTHENA-Lung01. o Accepted for priority review the BLA for V116 for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults based in part on STRIDE-3. • In the EU: o Approved KEYTRUDA in combination with chemotherapy for the 1L treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (CPS >/=1) based on KN-859. o Approved KEYTRUDA in combination with gemcitabine and cisplatin for the 1L treatment of patients with locally advanced unresectable or metastatic biliary tract cancer based on KN-966. o Approved PREVYMIS for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk. 1. Trial conducted in collaboration with Seagen (now Pfizer) and Astellas 2. Collaboration with Daiichi Sankyo 3. Collaboration with Moderna 4. Collaboration with Kelun-Biotech • Presented results from Phase 3 STRIDE-3 study evaluating V116, an investigational 21- valent pneumococcal conjugate vaccine for adults, at World Vaccine Congress West Coast. • Announced Phase 3 KN-564 trial met its key secondary endpoint of overall survival for the adjuvant treatment of patients with renal cell carcinoma at a higher risk of recurrence following nephrectomy. • Announced positive three year follow-up data from the Phase 2b randomized KN- 942/mRNA-4157-P201 study evaluating V9403 in combination with KEYTRUDA for the treatment of patients with resected high-risk stage III/IV melanoma following complete resection. • Announced Phase 3 AMBASSADOR (A031501)/KN-123 trial statistically significant and clinically meaningful improvement in disease-free survival vs observation for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma and locally advanced resectable urothelial carcinoma. • Announced Phase 3 KN-564 trial demonstrated significant improvement in overall survival for the treatment of patients with renal cell carcinoma at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. • Initiated Phase 3 trials across oncology pipeline for: o V940/mRNA-4157 3 in combination with KEYTRUDA for the adjuvant treatment of patients with certain types of resected non-small cell lung cancer o Bomedemstat for the treatment of certain patients with essential thrombocythemia o Nemtabrutinib for the treatment of certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma o MK-28704 for the treatment of certain patients with non-small cell lung cancer or endometrial carcinoma o MK-5684 for the treatment of certain patients with metastatic castration- resistant prostate cancer -- 31 of 32 -- Phase 2 Phase 3 Under regulatory review Oncology V181 Dengue Virus Vaccines Infectious diseases MK-8189 4 Schizophrenia Neuroscience Gefapixant (MK-7264)5 Cough (US) General medicine General medicine As of February 26, 2024 Infectious diseases Oncology Oncology MK-6024 (efinopegdutide) NASH MK-8527 HIV-1 prevention MK-8591B (islatravir+MK-8507)1 HIV-1 infection MK-8591D (islatravir+lenacapavir)2 HIV-1 infection MK-1022 (patritumab deruxtecan) NSCLC (EU) MK-1026 (nemtabrutinib) Hematological Malignancies MK-1308A (quavonlimab +pembrolizumab) RCC MK-2870 Endometrial NSCLC MK-3543 (bomedemstat) Myeloproliferative Disorders KEYTRUDA (MK-3475) CSCC (EU) Hepatocellular (EU) Mesothelioma Ovarian SCLC MK-3475A (pembro lizumab +hyaluronidase) NSCLC MK-4280A (favezelimab +pembrolizumab) CRC Hematological Malignancies MK-5684 Prostate WELIREG (MK-6482) RCC (EU) LENVIMA (MK-7902) Esophageal Gastric LYNPARZA (MK-7339) NSCLC SCLC MK-7684A (vibostolimab +pembrolizumab) Melanoma NSCLC SCLC V940 Melanoma NSCLC MK-8591A (doravirine+islatravir)2 HIV-1 Infection KEYTRUDA (MK-3475) Resectable NSCLC (EU, JPN) 1L Urothelial (EU, JPN) 1L HER2- Gastric (JPN) 1L Biliary (JPN) Endometrial Carcinoma (US) Cervical (EU) MK-1022 (patritumab deruxtecan) NSCLC (US) WELIREG (MK-6482) Certain VHL tumors (EU) Advanced RCC (EU) MK-2060 Thrombosis MK-5475 Pulmonary Arterial Hypertension MK-7962 (sotatercept) Pulmonary Hypertension due to Left Heart Disease Cardiovascular MK-4280A (favezelimab+pembrolizu mab) Bladder cSCC Endometrial Esophageal Melanoma RCC MK-5890 (boserolimab) Neoplasm Malignant KEYTRUDA (MK-3475) Advanced Solid Tumors Prostate KEYTRUDA (MK-3475A) cSCC MK-4280 (favezelimab) NSCLC LYNPARZA (MK-7339) Advanced Solid Tumors LENVIMA (MK-7902) HNSCC WELIREG (MK-6482) Endometrial Esophageal HCC Prostate Rare Cancers MK-7684A (vibostolimab +pembrolizumab) Biliary Bladder Breast Cervical CRC Endometrial Esophageal Gastric HCC HNSCC Ovarian Prostate MK-1308 (quavonlimab) NSCLC MK-1308A (quavonlimab +pembrolizumab) CRC MK-2140 (zilovertamab vedotin) Hematological Malignancies MK-2400 (ifinatamab deruxtecan) SCLC MK-2870 Neoplasm Malignant Broad and innovative pipeline to address significant unmet medical needs 32 Vaccines MK-1654 (clesrovimab) Respiratory Syncytial Virus (RSV) 1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials 3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma 5FDA issued CRL in December 2023 Cardiovascular V116 Pneumococcal conjugate vaccine, adult (EU) MK-7240 (tulisokibart) Ulcerative Colitis Immunology MK-0616 Hypercholesterolemia MK-7962 (sotatercept) Pulmonary Arterial Hypertension (US, EU) Cardiovascular LAGEVRIO (MK-4482)3 COVID-19 antiviral Vaccines V116 Pneumococcal conjugate vaccine, adult (US) MK-6194 Systemic Lupus Erythematosus Immunology -- 32 of 32 --